BioXcel Therapeutics, Inc.
BTAINASDAQHealthcare● Active
$1.09
$-0.02(-1.36%)
Market Cap$33656584
P/E Ratio—
52W High$8.08
52W Low$1.01
BioXcel Therapeutics, Inc.（BTAI）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · BTAI · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.64M | $2.27M | $1.38M | $0.38M | $0.00M |
| Cost of Revenue | $0.16M | $2.14M | $1.26M | $0.02M | $0.00M |
| Gross Profit | $0.48M | $0.12M | $0.12M | $0.35M | $0.00M |
| Gross Margin %(computed) | 74.45% | 5.43% | 8.70% | 94.67% | — |
| Operating Expenses | |||||
| R&D Expenses | $30.25M | $30.43M | $84.33M | $91.24M | $52.71M |
| G&A Expenses | $20.09M | $33.10M | $63.51M | $55.76M | $54.23M |
| Total Operating Expenses | $50.74M | $67.37M | $171.90M | $160.00M | $106.94M |
| Operating Income | ($50.27M) | ($67.25M) | ($171.78M) | ($159.65M) | ($106.94M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $1.07M | $2.60M | $5.65M | $2.53M | $0.00M |
| Interest Expense | $16.98M | $15.13M | $13.31M | $8.21M | $0.04M |
| Income Before Tax | ($69.90M) | ($59.60M) | ($179.05M) | ($165.76M) | ($106.93M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($69.90M) | ($59.60M) | ($179.05M) | ($165.76M) | ($106.93M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.73 | $-23.51 | $-98.35 | $-94.67 | $-64.87 |
| Wtd Avg Shares | 12.21M | 2.54M | 1.82M | 1.75M | 1.65M |
| EBITDA | ($52.61M) | ($44.16M) | ($165.42M) | ($157.22M) | ($106.59M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · M
深入了解BioXcel Therapeutics, Inc.
关于BioXcel Therapeutics, Inc.（BTAI）损益表
BioXcel Therapeutics, Inc.（BTAI）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，BTAI实现营收$0.00B，毛利润$0.00B（毛利率74.45%），净利润($0.07B)（净利率-10887.38%）。
常见问题
BTAI · 4 问BioXcel Therapeutics, Inc.（BTAI）2025财年营收为$0.00B，同比down71.7%。
BTAI revenueBTAI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09